Open AccessAnti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions
Author(s) -
Julio C. Chávez,
Farah Yassine,
José Sandoval-Sus,
Mohamed A. KharfanDabaja
Publication year - 2021
Publication title -
international journal of hematologic oncology
Language(s) - English
Resource type - Journals
eISSN - 2045-1407
pISSN - 2045-1393
DOI - 10.2217/ijh-2020-0021
Subject(s) - chimeric antigen receptor , cd19 , medicine , lymphoma , b cell , antigen , refractory (planetary science) , cell therapy , oncology , cancer research , cell , t cell , immunology , biology , immune system , antibody , genetics , astrobiology
Aims: To review recent data and relevant of the role of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin lymphoma (NHL). Methods: Review and compilation of the most recent and relevant data published in full text and abstract forms of anti-CD19 CAR T-cell therapy for B-cell NHL. Results: Different anti-CD19 CAR T-cell therapy products have been tested and shown significant clinical activity across B-cell NHL patients. The objective responses in relapsed DLBCL, FL and MCL were 50–83%, 83–93% and 93%, respectively. Conclusions: Anti-CD19 CAR T-cell therapy is a viable option for poor risk refractory B-cell NHLs.